(PCRX) Pacira BioSciences - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 984m USD | Total Return: -5.3% in 12m

Stock Pain Management, Injectable Suspensions, Cryoanalgesia, Gene Therapy
Total Rating 33
Risk 71
Buy Signal -0.67
Drug Manufacturers - Specialty & Generic +0.7
Pharmaceuticals -0.1
Market Cap: 984m
Avg Trading Vol: 14.8M USD
ATR: 3.90%
Peers RS (IBD): 29.7
Risk 5d forecast
Volatility45.8%
Rel. Tail Risk-6.48%
Reward TTM
Sharpe Ratio-0.12
Alpha-9.09
Character TTM
Beta-0.314
Beta Downside1.139
Drawdowns 3y
Max DD75.37%
CAGR/Max DD-0.24
EPS (Earnings per Share) EPS (Earnings per Share) of PCRX over the last years for every Quarter: "2021-03": 0.53, "2021-06": 0.77, "2021-09": 0.72, "2021-12": 0.97, "2022-03": 0.64, "2022-06": 0.51, "2022-09": 0.64, "2022-12": 0.8, "2023-03": 0.53, "2023-06": 0.78, "2023-09": 0.72, "2023-12": 0.89, "2024-03": 0.62, "2024-06": 0.89, "2024-09": 0.79, "2024-12": 0.91, "2025-03": 0.62, "2025-06": -0.11, "2025-09": 0.7, "2025-12": 0.57, "2026-03": 0,
EPS CAGR: -30.35%
EPS Trend: -39.0%
Last SUE: -2.26
Qual. Beats: 0
Revenue Revenue of PCRX over the last years for every Quarter: 2021-03: 119.027, 2021-06: 135.59, 2021-09: 127.722, 2021-12: 159.194, 2022-03: 157.991, 2022-06: 169.411, 2022-09: 167.466, 2022-12: 171.955, 2023-03: 160.341, 2023-06: 169.467, 2023-09: 163.926, 2023-12: 181.244, 2024-03: 167.117, 2024-06: 178.023, 2024-09: 168.573, 2024-12: 187.253, 2025-03: 168.923, 2025-06: 181.099, 2025-09: 179.516, 2025-12: 196.873, 2026-03: null,
Rev. CAGR: 6.04%
Rev. Trend: 72.0%
Last SUE: -1.35
Qual. Beats: 0
Risks
Fundamental:

P/E ratio: 143.0

Description: PCRX Pacira BioSciences

Pacira BioSciences, Inc. (PCRX) develops and sells non-opioid pain management and regenerative health solutions. The companys product portfolio includes EXPAREL for postsurgical pain, ZILRETTA for osteoarthritis knee pain, and the iovera system, a cryoanalgesia device. Pacira also has a veterinary product, NOCITA, and is developing a gene therapy platform, PCRX-201, for osteoarthritis.

The pharmaceutical sector is characterized by high research and development costs and extensive regulatory approval processes. Paciras business model focuses on developing specialized, non-opioid alternatives for pain management, addressing a significant market need for addiction-sparing treatments.

For more detailed financial analysis and performance metrics, further research on ValueRay is recommended.

Headlines to Watch Out For
  • EXPAREL sales growth drives revenue
  • ZILRETTA adoption expands market share
  • iovera system sales contribute to portfolio diversification
  • Pipeline development for PCRX-201 impacts future valuation
  • Regulatory approvals for new indications affect market access
Piotroski VR‑10 (Strict, 0-10) 5.5
Net Income: 7.03m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.70 > 1.0
NWC/Revenue: 58.84% < 20% (prev 62.09%; Δ -3.25% < -1%)
CFO/TA 0.12 > 3% & CFO 152.0m > Net Income 7.03m
Net Debt (295.8m) to EBITDA (121.8m): 2.43 < 3
Current Ratio: 4.54 > 1.5 & < 3
Outstanding Shares: last quarter (43.0m) vs 12m ago -12.35% < -2%
Gross Margin: 77.41% > 18% (prev 0.76%; Δ 7.67k% > 0.5%)
Asset Turnover: 51.55% > 50% (prev 45.12%; Δ 6.43% > 0%)
Interest Coverage Ratio: 1.83 > 6 (EBITDA TTM 121.8m / Interest Expense TTM 16.8m)
Altman Z'' 1.49
A: 0.34 (Total Current Assets 548.0m - Total Current Liabilities 120.6m) / Total Assets 1.26b
B: -0.16 (Retained Earnings -199.3m / Total Assets 1.26b)
C: 0.02 (EBIT TTM 30.7m / Avg Total Assets 1.41b)
D: -0.34 (Book Value of Equity -194.9m / Total Liabilities 571.8m)
Altman-Z'' Score: 1.49 = BB
Beneish M -3.03
DSRI: 1.06 (Receivables 124.1m/113.3m, Revenue 726.4m/701.0m)
GMI: 0.98 (GM 77.41% / 75.69%)
AQI: 1.11 (AQ_t 0.42 / AQ_t-1 0.38)
SGI: 1.04 (Revenue 726.4m / 701.0m)
TATA: -0.11 (NI 7.03m - CFO 152.0m) / TA 1.26b)
Beneish M-Score: -3.03 (Cap -4..+1) = AA
What is the price of PCRX shares? As of April 02, 2026, the stock is trading at USD 22.60 with a total of 657,763 shares traded.
Over the past week, the price has changed by -2.98%, over one month by +7.10%, over three months by -6.83% and over the past year by -5.32%.
Is PCRX a buy, sell or hold? Pacira BioSciences has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold PCRX.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 3
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the PCRX price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 28.7 27%
Analysts Target Price 28.7 27%
PCRX Fundamental Data Overview as of 29 March 2026
P/E Trailing = 143.0
P/E Forward = 9.1075
P/S = 1.3551
P/B = 1.2934
P/EG = 11.2121
Revenue TTM = 726.4m USD
EBIT TTM = 30.7m USD
EBITDA TTM = 121.8m USD
Long Term Debt = 372.2m USD (from longTermDebt, last quarter)
Short Term Debt = 9.84m USD (from shortTermDebt, last quarter)
Debt = 454.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 295.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.20b USD (984.3m + Debt 454.4m - CCE 238.4m)
Interest Coverage Ratio = 1.83 (Ebit TTM 30.7m / Interest Expense TTM 16.8m)
EV/FCF = 8.78x (Enterprise Value 1.20b / FCF TTM 136.7m)
FCF Yield = 11.39% (FCF TTM 136.7m / Enterprise Value 1.20b)
FCF Margin = 18.81% (FCF TTM 136.7m / Revenue TTM 726.4m)
Net Margin = 0.97% (Net Income TTM 7.03m / Revenue TTM 726.4m)
Gross Margin = 77.41% ((Revenue TTM 726.4m - Cost of Revenue TTM 164.1m) / Revenue TTM)
Gross Margin QoQ = 72.26% (prev 80.91%)
Tobins Q-Ratio = 0.95 (Enterprise Value 1.20b / Total Assets 1.26b)
Interest Expense / Debt = 0.86% (Interest Expense 3.89m / Debt 454.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = 24.3m (EBIT 30.7m * (1 - 21.00%))
Current Ratio = 4.54 (Total Current Assets 548.0m / Total Current Liabilities 120.6m)
Debt / Equity = 0.66 (Debt 454.4m / totalStockholderEquity, last quarter 693.1m)
Debt / EBITDA = 2.43 (Net Debt 295.8m / EBITDA 121.8m)
Debt / FCF = 2.16 (Net Debt 295.8m / FCF TTM 136.7m)
Total Stockholder Equity = 744.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.50% (Net Income 7.03m / Total Assets 1.26b)
RoE = 0.95% (Net Income TTM 7.03m / Total Stockholder Equity 744.2m)
RoCE = 2.75% (EBIT 30.7m / Capital Employed (Equity 744.2m + L.T.Debt 372.2m))
RoIC = 1.99% (NOPAT 24.3m / Invested Capital 1.22b)
WACC = 3.55% (E(984.3m)/V(1.44b) * Re(4.88%) + D(454.4m)/V(1.44b) * Rd(0.86%) * (1-Tc(0.21)))
Discount Rate = 4.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -9.14%
[DCF] Terminal Value 88.26% ; FCFF base≈153.5m ; Y1≈185.6m ; Y5≈302.6m
[DCF] Fair Price = 209.9 (EV 8.80b - Net Debt 295.8m = Equity 8.50b / Shares 40.5m; r=6.0% [WACC]; 5y FCF grow 22.37% → 3.0% )
EPS Correlation: -38.96 | EPS CAGR: -30.35% | SUE: -2.26 | # QB: 0
Revenue Correlation: 72.04 | Revenue CAGR: 6.04% | SUE: -1.35 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.71 | Chg7d=+0.023 | Chg30d=-0.137 | Revisions Net=-2 | Analysts=7
EPS current Year (2026-12-31): EPS=2.65 | Chg7d=-0.028 | Chg30d=-0.761 | Revisions Net=-6 | Growth EPS=-0.1% | Growth Revenue=+4.9%
EPS next Year (2027-12-31): EPS=3.49 | Chg7d=-0.088 | Chg30d=-0.233 | Revisions Net=-1 | Growth EPS=+32.0% | Growth Revenue=+9.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.2% (Discount Rate 7.9% - Earnings Yield 0.7%)
[Growth] Growth Spread = -2.2% (Analyst 5.1% - Implied 7.2%)
Additional Sources for PCRX Stock Fund Manager Positions: Dataroma · Stockcircle